Related references
Note: Only part of the references are listed.Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia
Ralph Boccia et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia
Richard Vollenberg et al.
HAEMATOLOGICA (2019)
Immune Thrombocytopenia
Nichola Cooper et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia
Ivy Altomare et al.
BLOOD (2019)
Real-World Experience with Fostamatinib in Patients with Immune Thrombocytopenia at an Academic Medical Center
David Hughes et al.
BLOOD (2019)
Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program
James B. Bussel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
Drew Provan et al.
BLOOD ADVANCES (2019)
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials
James Bussel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Fostamatinib for persistent/chronic adult immune thrombocytopenia
Adrian Newland et al.
IMMUNOTHERAPY (2018)
Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program
Anne-Marie Duliege et al.
BLOOD (2018)
Evidence-based management of immune thrombocytopenia: ASH guideline update
Cindy E. Neunert et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2018)
Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
Anne Zufferey et al.
JOURNAL OF CLINICAL MEDICINE (2017)
State of the art - how I manage immune thrombocytopenia
Nichola Cooper
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Is ITP a thrombophilic disorder?
Francesco Rodeghiero
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical studies
Paul Martin et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies
Paul Martin et al.
CLINICAL THERAPEUTICS (2015)
Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies
Muhammad Baluom et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Immune Thrombocytopenia
Gaurav Kistangari et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2013)
Determining a definite diagnosis of primary immune thrombocytopenia by medical record review
Deirdra R. Terrell et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Fostamatinib, a Syk-Kinase Inhibitor, Does Not Affect Methotrexate Pharmacokinetics in Patients With Rheumatoid Arthritis
Muhammad Baluom et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Increased Number of Tc17 and Correlation with Th17 Cells in Patients with Immune Thrombocytopenia
Yu Hu et al.
PLOS ONE (2011)
Piecing Together the Humoral and Cellular Mechanisms of Immune Thrombocytopenia
Lisa J. Toltl et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2011)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in Fc epsilon RI-activated RBL-2H3 basophilic cells
Michael P. Sanderson et al.
CELLULAR IMMUNOLOGY (2010)
Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation
David J. Sweeny et al.
DRUG METABOLISM AND DISPOSITION (2010)
Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk
Anna Podolanczuk et al.
BLOOD (2009)
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Francesco Rodeghiero et al.
BLOOD (2009)
The ITP syndrome: pathogenic and clinical diversity
Douglas B. Cines et al.
BLOOD (2009)
Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production
Diane Nugent et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura
Jingbo Zhang et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Antiplatelet Antibodies in Chronic Immune Thrombocytopenia and Their Role in Platelet Destruction and Defective Platelet Production
Robert McMillan
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2009)
Costimulation of dectin-1 and DC-SIGN triggers the arachidonic acid cascade in human monocyte-derived dendritic cells
Isela Valera et al.
JOURNAL OF IMMUNOLOGY (2008)
Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal
M. A. Feudjo-Tepie et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor
Polly R. Pine et al.
CLINICAL IMMUNOLOGY (2007)
The epidemiology of immune thrombocytopenic purpura
Patrick F. Fogarty et al.
CURRENT OPINION IN HEMATOLOGY (2007)
Reduced Cd4(+)Cd25(+) T cells in patients with idiopathic thrombocytopenic purpura
Miho Sakakura et al.
THROMBOSIS RESEARCH (2007)
R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation
Sylvia Braselmann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Prevalence of immune thrombocytopenia: analyses of administrative data
J. B. Segal et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP
R McMillan et al.
BLOOD (2004)
Medical progress: Immune thrombocytopenic purpura.
DB Cines et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts
YC Cohen et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Share Paper
